New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:21 EDTALKS, BIIBAlkermes issued patent for fumarate pro-drug, says Citigroup
Citigroup notes that Alkermes (ALKS) was issued a United States patent for its pro-drug of mono-methyl fumarate, the active ingredient in Biogen's (BIIB) Tecfidera. Citi views the patent as supporting the regulatory potential of ALKS 8700, and notes the drug is a long-term threat to Tecfidera. The firm says Phase 1 data expected by year-end 2014 could be meaningful and keeps a Buy rating on Alkermes with a $60 price target.
News For ALKS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 17, 2014
07:16 EDTALKSMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 13, 2014
11:54 EDTALKSJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use